[ad_1]
Rabat – The Casablanca-based Oncorad Group has become the first cancer treatment center in Africa to publish research in “Advances in Radiation Oncology,” in partnership with the American Society for Radiation Oncology (ASTRO).
The featured study, carried out by Oncorad’s research team at the Le Littoral Clinic, explores a combined treatment protocol for aggressive prostate cancer, integrating high-dose-rate (HDR) brachytherapy with external beam radiotherapy.
Conducted on a cohort of more than 120 patients, including several international cases, the research demonstrated a 92% remission rate with no significant toxicity. These results are consistent with the highest global standards in cancer care.
The project was developed by a multidisciplinary Moroccan team led by principal investigator Dr. Hamza Samlali and coordinated by Dr. Najlaa Assaid. The medical physics team included Youness Khobbaizi, Omar Hanicha, Mahdi Abou El Houda, and Sanaa Nabil, under the leadership of Professor Redouane Samlali, founder of Oncorad Group.
The initiative also received academic support from Professor Hassan Jouhadi, head of oncology at the University Hospital of Casablanca and professor at the city’s Faculty of Medicine.
Read also: Oncorad Group Celebrates First Cryoablation Procedure in Morocco, North Africa
This publication represents the largest clinical series of its kind from Africa and the MENA region and positions Oncorad as a leading regional actor in cancer treatment and research. The study’s inclusion of international patients further underscores its transnational relevance.
Beyond this achievement, Oncorad’s research unit continues to pursue a wide range of projects focused on locally adapted, innovative cancer care solutions. These include advances in robotic surgery, state-of-the-art radiotherapy techniques, and investigations into the genetic and biological dimensions of cancer—all supported through collaborations with national and international partners.
Advances in Radiation Oncology is globally recognized for promoting impactful clinical research, particularly from resource-limited settings. With an impact factor of 2.7 and listings in leading databases such as PubMed Central, Scopus, and Web of Science, the journal’s publication of Oncorad’s study marks a significant milestone for African contributions to global medical literature.
By bringing African data and perspectives to the forefront of scientific dialogue, Oncorad aims to support the development of more inclusive, evidence-based treatment strategies that benefit cancer patients across low- and middle-income countries.
[ad_2]
Source link